OnabotulinumtoxinA detrusor injection improves female sexual function in women with overactive bladder wet syndrome.
OBJECTIVES
The correlation between changes in sexual function and improvements in LUTD in patients treated with OnabotulinumtoxinA (onaBoNT-A) detrusor injection is unclear and limited only to women with neurogenic OAB. The aim of this study was to evaluate the impact of OnabotulinumtoxinA (onaBoNT-A) injection on sexual function in women undergoing this treatment for idiopathic wet overactive bladder (OAB).


STUDY DESIGN
This is a pilot three-center observational study including women affected by idiopathic wet overactive bladder refractory to standard conservative treatments and underwent onaBoNT-A injection. Sexuality was assessed using the Female Sexual Function Index (FSFI). A 3-day voiding diary, OAB screener questionnaire (OAB-S), and the international consultation on incontinence questionnaire short form (ICIQ-sf) were completed before and 3 months after onaBoNT-A injection to evaluate OAB symptoms.


RESULTS
All the 32 enrolled patients were included for statistical analysis. These patients received 100U of onaBoNT-A. Significant improvement of many FSFI domains was found. Only desire and pain domains had no significant improvements. The FSFI total score showed a significant improvement (P 0.0008). Clinical efficacy has been documented by voiding diaries, OAB-S scores, and ICIQ-sf scores. Correlation between UUI episodes and FSFI total score was statistically significant (r = -0.73; p = 0.04) while no significant correlation was found between the number of micturition and FSFI total score.


CONCLUSION
Women who underwent successful OnaBoNT-A detrusor injection to treat wet OAB, showed an improvement in sexual function due to the significant correlation between the improvement of urinary urge incontinence and a better gratification of sexuality.
['Balzarro|Matteo|M|', 'Rubilotta|Emanuele|E|', 'Braga|Andrea|A|', 'Bassi|Silvia|S|', 'Processali|Tania|T|', 'Artibani|Walter|W|', 'Serati|Maurizio|M|']
D065087:Acetylcholine Release Inhibitors D000328:Adult D000368:Aged D019274:Botulinum Toxins, Type A D005260:Female D006801:Humans D015552:Injections, Intralesional D008875:Middle Aged D010865:Pilot Projects D011788:Quality of Life D012735:Sexual Dysfunction, Physiological D016896:Treatment Outcome D001743:Urinary Bladder D053201:Urinary Bladder, Overactive D014554:Urination
OnabotulinumtoxinA Overactive bladder Female sexual dysfunction